Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (603)	4/14/2006 1:49:54 PM
From: scaram(o)uche	of 6136

eximiaspharm.com Oncology is the area of medicine that studies the cause, diagnosis and treatment of cancer. Since 1990, more than 18,000,000 Americans have been diagnosed with some form of cancer. The American Cancer Society estimates over to 1.3 million Americans will be diagnosed with cancer in 2005. Over half a million cancer patients will die this year. Eximias’ lead oncology product, THYMITAQ® (nolatrexed), completed enrollment in a pivotal Phase III clinical trial for inoperable primary liver cancer (hepatocellular carcinoma or HCC) in April 2005. HCC is a rapidly fatal disease, and there is no FDA-approved treatment in the United States or in the European Union. In August 2005, the Company announced that the Phase III clinical study evaluating THYMITAQ® in patients with unresectable hepatocellular carcinoma (inoperable primary liver cancer) failed to achieve its primary endpoint, a survival benefit versus doxorubicin. Additional analyses have been conducted with the data from the Phase III study to better understand the results of the survival analysis and steer future activities.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next